Comparison of tandem mass spectrometry to fluorimetry for newborn screening of LSDs
Open Access
- 12 June 2017
- journal article
- other
- Published by Elsevier BV in Molecular Genetics and Metabolism Reports
- Vol. 12, 80-81
- https://doi.org/10.1016/j.ymgmr.2017.05.004
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Mass Spectrometry but Not Fluorimetry Distinguishes Affected and Pseudodeficiency Patients in Newborn Screening for Pompe DiseaseClinical Chemistry, 2017
- Misinformation regarding tandem mass spectrometric vs fluorometric assays to screen newborns for LSDsMolecular Genetics and Metabolism Reports, 2017
- Liquid Chromatography–Tandem Mass Spectrometry Assay of Leukocyte Acid α-Glucosidase for Post-Newborn Screening Evaluation of Pompe DiseaseClinical Chemistry, 2017
- Newborn Screening for Lysosomal Storage Diseases: A Concise Review of the Literature on Screening Methods, Therapeutic Possibilities and Regional ProgramsInternational Journal of Neonatal Screening, 2017
- Pilot study of newborn screening for six lysosomal storage diseases using Tandem Mass SpectrometryMolecular Genetics and Metabolism, 2016
- Tandem Mass Spectrometry Has a Larger Analytical Range than Fluorescence Assays of Lysosomal Enzymes: Application to Newborn Screening and Diagnosis of Mucopolysaccharidoses Types II, IVA, and VIClinical Chemistry, 2015
- Newborn Screening for Lysosomal Storage DiseasesClinical Chemistry, 2015
- Identification of Infants at Risk for Developing Fabry, Pompe, or Mucopolysaccharidosis-I from Newborn Blood Spots by Tandem Mass SpectrometryThe Journal of Pediatrics, 2013